Status:
COMPLETED
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Lead Sponsor:
Alexion Pharmaceuticals, Inc.
Collaborating Sponsors:
Procter and Gamble
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
During a heart bypass procedure, a substance called "complement" is activated by the body. This "complement activation" causes an inflammatory response that can lead to side affects such as chest pain...
Eligibility Criteria
Inclusion
- be at least 18 years of age;
- have 2 or more of the following risk factors:
- • diabetes mellitus; • repeat CABG; • the need for urgent intervention, defined according to the ACC/AHA guidelines as being patients who are required to stay in the hospital due to medical factors, but may be scheduled and operated on within a normal scheduling routine, excluding patients who have had an MI within 48 hours of CABG; • female; • history of a neurologic event (cerebrovascular accident, transient ischemic attack or carotid endarterectomy); • history of congestive heart failure (NYHA CHF Class III or IV); • history of 2 MIs, or an MI that occurred greater than 48 hours but less than 4 weeks prior to CABG;
- provide Informed Consent.
Exclusion
- requires salvage intervention as defined by the ACC/AHA guidelines 10 as being ongoing cardiopulmonary resuscitation on the way to the operating room;
- has current cardiogenic shock, acute left ventricular rupture, acute septal rupture or acute papillary muscle rupture;
- has any active bacterial or other infection which is clinically significant, in the opinion of the Investigator (e.g. evaluate the evidence based on WBC, temperature, cultures etc. as appropriate for the patient);
- has a known or suspected hereditary complement deficiency;
- has participated in any other investigational drug study or was exposed to an investigational agent or device within 30 days of randomization;
- is receiving, or is planning to receive, any other investigational drug or device, or will participate in any other research study within 30 days of randomization;
- is pregnant or breast-feeding.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT00088179
Start Date
July 1 2004
End Date
October 1 2005
Last Update
February 22 2018
Active Locations (188)
Enter a location and click search to find clinical trials sorted by distance.
1
Brookwood Medical Center
Birmingham, Alabama, United States, 35209
2
Baptist Medical Center Princeton
Birmingham, Alabama, United States, 35211
3
Baptist Health Systems Montclair
Birmingham, Alabama, United States, 35213
4
Medical Center East Hospital
Birmingham, Alabama, United States, 35235